Elevated levels of C3, C4, and CH50 of the complement system in ICU and non‐ICU patients with COVID‐19

PURPOSE: SARS‐CoV‐2 infection has spread in each corner of the world. Many health systems have dealt with it intensively. The complement system is an instrumental component in the inflammatory immune response and plays a role in the activation of blood coagulation. Our understanding of the pathophysiology of SARS‐CoV‐2 is still limited but is constantly expanding. This study aimed to determine changes in the complement system in intensive care unit (ICU) and non‐ICU patients with COVID‐19. METHODS: In a cross‐sectional study, plasma levels of C3, C4, and CH50 were determined in two groups of ICU and non‐ICU patients with COVID‐19 to understand the potential effects of SARS‐CoV‐2 on the innate immune system. The assays of C3 and C4 were conducted using turbidimetry method. The CH50 test was conducted using the functional method. RESULTS: The present study revealed that the C3, C4, and CH50 plasma levels were 142.48 ± 30.38 mg/dL, 32.58 ± 8.78 mg/dL, and 61.74 ± 19.54%, respectively. These results indicate high levels of complement components C3 and C4 and complement function (CH50) in patients with COVID‐19 than normal ranges. Plasma levels of C3, C4, and CH50 were higher in ICU patients than in non‐ICU COVID‐19 groups. CONCLUSION: These results indicate that the innate immune system was activated in both ICU and non‐ICU patients in response to SARS‐CoV‐2 infection. Further studies with a larger number of COVID‐19 patients and additional testing of complement components (C3a and C5a) may reveal the role of COVID‐19 infection in the activation of the complement system.